{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:35:18Z","timestamp":1772120118273,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s13346-021-01109-y","type":"journal-article","created":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T19:03:41Z","timestamp":1643569421000},"page":"2561-2568","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A recombinant adenoviral vector with a specific tropism to CD4-positive cells: a new tool for HIV-1 inhibition"],"prefix":"10.1007","volume":"12","author":[{"given":"Abtin","family":"Behmardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8207-6572","authenticated-orcid":false,"given":"Touraj","family":"Farazmandfar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"key":"1109_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2016.08.031","author":"DS Clutter","year":"2016","unstructured":"Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV-1 drug resistance and resistance testing. Infect Genet Evol. 2016. https:\/\/doi.org\/10.1016\/j.meegid.2016.08.031.","journal-title":"Infect Genet Evol"},{"key":"1109_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.03.005","author":"DM Margolis","year":"2020","unstructured":"Margolis DM, Archin NM, Cohen MS, Eron JJ, Ferrari G, Garcia JV, et al. Curing HIV: seeking to target and clear persistent infection. Cell. 2020. https:\/\/doi.org\/10.1016\/j.cell.2020.03.005.","journal-title":"Cell"},{"key":"1109_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000344","author":"UM Parikh","year":"2017","unstructured":"Parikh UM, McCormick K, van Zyl G, Mellors JW. Future technologies for monitoring HIV drug resistance and cure. Curr Opin HIV AIDS. 2017. https:\/\/doi.org\/10.1097\/COH.0000000000000344.","journal-title":"Curr Opin HIV AIDS"},{"key":"1109_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-8922-5_1","author":"N D\u00fczg\u00fcne\u015f","year":"2019","unstructured":"D\u00fczg\u00fcne\u015f N. Origins of suicide gene therapy. Methods Mol Biol. 2019. https:\/\/doi.org\/10.1007\/978-1-4939-8922-5_1.","journal-title":"Methods Mol Biol"},{"key":"1109_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/s0167-5699(99)01550-9","author":"S Lal","year":"2000","unstructured":"Lal S, Lauer UM, Niethammer D, Beck JF, Schlegel PG. Suicide genes: past, present and future perspectives. Immunol Today. 2000. https:\/\/doi.org\/10.1016\/s0167-5699(99)01550-9.","journal-title":"Immunol Today"},{"key":"1109_CR6","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M005150200","author":"P Dupraz","year":"2000","unstructured":"Dupraz P, Cottet S, Hamburger F, Dolci W, Felley-Bosco E, Thorens B. Dominant negative MyD88 proteins inhibit interleukin-1\u03b2\/interferon-\u03b3-mediated induction of nuclear factor \u03baB-dependent nitrite production and apoptosis in \u03b2 cells. J Biol Chem. 2000. https:\/\/doi.org\/10.1074\/jbc.M005150200.","journal-title":"J Biol Chem"},{"key":"1109_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302514","author":"RR Pochampally","year":"2005","unstructured":"Pochampally RR, Horwitz EM, DiGirolamo CM, Stokes DS, Prockop DJ. Correction of a mineralization defect by overexpression of a wild-type cDNA for COL1A1 in marrow stromal cells (MSCs) from a patient with osteogenesis imperfecta: a strategy for rescuing mutations that produce dominant-negative protein defects. Gene Ther. 2005. https:\/\/doi.org\/10.1038\/sj.gt.3302514.","journal-title":"Gene Ther"},{"key":"1109_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1997.tb00521.x","author":"J Wands","year":"1997","unstructured":"Wands J, Geissler M, Putlitz J, Blum H, Weizs\u00e4cker FV, Mohr L, et al. Nucleic acid-based antiviral and gene therapy of chronic hepatitis B infection. J Gastroenterol Hepatol. 1997. https:\/\/doi.org\/10.1111\/j.1440-1746.1997.tb00521.x.","journal-title":"J Gastroenterol Hepatol"},{"key":"1109_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22040563","author":"V Sardone","year":"2017","unstructured":"Sardone V, Zhou H, Muntoni F, Ferlini A, Falzarano MS. Antisense oligonucleotide-based therapy for neuromuscular disease. Molecules. 2017. https:\/\/doi.org\/10.3390\/molecules22040563.","journal-title":"Molecules"},{"key":"1109_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/s1525-0016(03)00165-5","author":"M-J Li","year":"2003","unstructured":"Li M-J, Bauer G, Michienzi A, Yee J-K, Lee N-S, Kim J, et al. Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther. 2003. https:\/\/doi.org\/10.1016\/s1525-0016(03)00165-5.","journal-title":"Mol Ther"},{"key":"1109_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-7-33","author":"HJ Unwalla","year":"2010","unstructured":"Unwalla HJ, Rossi JJ. A dual function TAR decoy serves as an anti-HIV siRNA delivery vehicle. Virol J. 2010. https:\/\/doi.org\/10.1186\/1743-422X-7-33.","journal-title":"Virol J"},{"key":"1109_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-79086-0_9","author":"J Haasnoot","year":"2009","unstructured":"Haasnoot J, Berkhout B. Nucleic acids-based therapeutics in the battle against pathogenic viruses. Handb Exp Pharmacol. 2009. https:\/\/doi.org\/10.1007\/978-3-540-79086-0_9.","journal-title":"Handb Exp Pharmacol"},{"key":"1109_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2007.12.008","author":"KB Spurgers","year":"2008","unstructured":"Spurgers KB, Sharkey CM, Warfield KL, Bavari S. Oligonucleotide antiviral therapeutics: antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Res. 2008. https:\/\/doi.org\/10.1016\/j.antiviral.2007.12.008.","journal-title":"Antiviral Res"},{"key":"1109_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/35053110","author":"E Bernstein","year":"2001","unstructured":"Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature. 2001. https:\/\/doi.org\/10.1038\/35053110.","journal-title":"Nature"},{"key":"1109_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/nature03868","author":"TP Chendrimada","year":"2005","unstructured":"Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, Nishikura K, et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature. 2005. https:\/\/doi.org\/10.1038\/nature03868.","journal-title":"Nature"},{"key":"1109_CR16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.171251798","author":"NJ Caplen","year":"2001","unstructured":"Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA. 2001. https:\/\/doi.org\/10.1073\/pnas.171251798.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1109_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0502-500","author":"NS Lee","year":"2002","unstructured":"Lee NS, Dohjima T, Bauer G, Li H, Li M-J, Ehsani A, et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol. 2002. https:\/\/doi.org\/10.1038\/nbt0502-500.","journal-title":"Nat Biotechnol"},{"key":"1109_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/nbt739","author":"H Xia","year":"2002","unstructured":"Xia H, Mao Q, Paulson HL, Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol. 2002. https:\/\/doi.org\/10.1038\/nbt739.","journal-title":"Nat Biotechnol"},{"key":"1109_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.03.005","author":"LM Humeau","year":"2004","unstructured":"Humeau LM, Binder GK, Lu X, Slepushkin V, Merling R, Echeagaray P, et al. Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol Ther. 2004. https:\/\/doi.org\/10.1016\/j.ymthe.2004.03.005.","journal-title":"Mol Ther"},{"key":"1109_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2008.04.001","author":"LL Snyder","year":"2008","unstructured":"Snyder LL, Esser JM, Pachuk CJ, Steel LF. Vector design for liver-specific expression of multiple interfering RNAs that target hepatitis B virus transcripts. Antiviral Res. 2008. https:\/\/doi.org\/10.1016\/j.antiviral.2008.04.001.","journal-title":"Antiviral Res"},{"key":"1109_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2008.11.016","author":"J Park","year":"2009","unstructured":"Park J, Nadeau PE, Mergia A. Activity of TAR in inducible inhibition of HIV replication by foamy virus vector expressing siRNAs under the control of HIV LTR. Virus Res. 2009. https:\/\/doi.org\/10.1016\/j.virusres.2008.11.016.","journal-title":"Virus Res"},{"key":"1109_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1040","author":"HJ Unwalla","year":"2004","unstructured":"Unwalla HJ, Li M-J, Kim JD, Li HT, Ehsani A, Alluin J, et al. Negative feedback inhibition of HIV-1 by TAT-inducible expression of siRNA. Nat Biotechnol. 2004. https:\/\/doi.org\/10.1038\/nbt1040.","journal-title":"Nat Biotechnol"},{"key":"1109_CR23","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.80.4.1863-1873.2006","author":"HJ Unwalla","year":"2006","unstructured":"Unwalla HJ, Li H-T, Bahner I, Li M-J, Kohn D, Rossi JJ. Novel Pol II fusion promoter directs human immunodeficiency virus type 1-inducible coexpression of a short hairpin RNA and protein. J Virol. 2006. https:\/\/doi.org\/10.1128\/JVI.80.4.1863-1873.2006.","journal-title":"J Virol"},{"key":"1109_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/19.25.7225","author":"P Han","year":"1991","unstructured":"Han P, Brown R, Barsoum J. Transactivation of heterologous promoters by HIV-1 tat. Nucleic Acids Res. 1991. https:\/\/doi.org\/10.1093\/nar\/19.25.7225.","journal-title":"Nucleic Acids Res"},{"key":"1109_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2010.09.006","author":"VR Sanghvi","year":"2011","unstructured":"Sanghvi VR, Steel LF. Expression of interfering RNAs from an HIV-1 Tat-inducible chimeric promoter. Virus Res. 2011. https:\/\/doi.org\/10.1016\/j.virusres.2010.09.006.","journal-title":"Virus Res"},{"key":"1109_CR26","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.41.28837","author":"KT Jeang","year":"1999","unstructured":"Jeang KT, Xiao H, Rich EA. Multifaceted activities of the HIV-1 transactivator of transcription. Tat J Biol Chem. 1999. https:\/\/doi.org\/10.1074\/jbc.274.41.28837.","journal-title":"Tat J Biol Chem"},{"key":"1109_CR27","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2015.031","author":"T Farazmandfar","year":"2015","unstructured":"Farazmandfar T, Haghshenas MR, Shahbazi M. Inhibition of HIV-1 by a lentiviral vector with a novel Tat-inducible expression system and a specific tropism to the target cells. Hum Gene Ther. 2015. https:\/\/doi.org\/10.1089\/hum.2015.031.","journal-title":"Hum Gene Ther"},{"key":"1109_CR28","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2013.1812","author":"SY Kim","year":"2013","unstructured":"Kim SY, Kang S, Song JJ, Kim J-H. The effectiveness of the oncolytic activity induced by Ad5\/F35 adenoviral vector is dependent on the cumulative cellular conditions of survival and autophagy. Int J Oncol. 2013. https:\/\/doi.org\/10.3892\/ijo.2013.1812.","journal-title":"Int J Oncol"},{"key":"1109_CR29","doi-asserted-by":"publisher","DOI":"10.2174\/157488509788185123","author":"A Sharma","year":"2009","unstructured":"Sharma A, Tandon M, Bangari DS, Mittal SK. Adenoviral vector-based strategies for cancer therapy. Curr Drug ther. 2009. https:\/\/doi.org\/10.2174\/157488509788185123.","journal-title":"Curr Drug ther"},{"key":"1109_CR30","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm_00000306","author":"T Fukazawa","year":"2010","unstructured":"Fukazawa T, Matsuoka J, Yamatsuji T, Maeda Y, Durbin ML, Naomoto Y. Adenovirus-mediated cancer gene therapy and virotherapy. Int J Mol Med. 2010. https:\/\/doi.org\/10.3892\/ijmm_00000306.","journal-title":"Int J Mol Med"},{"key":"1109_CR31","doi-asserted-by":"publisher","DOI":"10.2174\/1566523213666131125095046","author":"WSM Wold","year":"2013","unstructured":"Wold WSM, Toth K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther. 2013. https:\/\/doi.org\/10.2174\/1566523213666131125095046.","journal-title":"Curr Gene Ther"},{"key":"1109_CR32","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.70.10.6839-6846.1996","author":"VN Krasnykh","year":"1996","unstructured":"Krasnykh VN, Mikheeva GV, Douglas JT, Curiel DT. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol. 1996. https:\/\/doi.org\/10.1128\/JVI.70.10.6839-6846.1996.","journal-title":"J Virol"},{"key":"1109_CR33","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.68.8.5239-5246.1994","author":"LJ Henry","year":"1994","unstructured":"Henry LJ, Xia D, Wilke ME, Deisenhofer J, Gerard RD. Characterization of the knob domain of the adenovirus type 5 fiber protein expressed in Escherichia coli. J Virol. 1994. https:\/\/doi.org\/10.1128\/JVI.68.8.5239-5246.1994.","journal-title":"J Virol"},{"key":"1109_CR34","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.69.5.2850-2857.1995","author":"SC Stevenson","year":"1995","unstructured":"Stevenson SC, Rollence M, White B, Weaver L, McClelland A. Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain. J Virol. 1995. https:\/\/doi.org\/10.1128\/JVI.69.5.2850-2857.1995.","journal-title":"J Virol"},{"key":"1109_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004961","author":"M Holmes","year":"2015","unstructured":"Holmes M, Zhang F, Bieniasz PD. Single-cell and single-cycle analysis of HIV-1 replication. PLoS Pathog. 2015. https:\/\/doi.org\/10.1371\/journal.ppat.1004961.","journal-title":"PLoS Pathog"},{"key":"1109_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-016-0228-5","author":"Y Yazdani","year":"2016","unstructured":"Yazdani Y, Farazmandfar T, Azadeh H, Zekavatian Z. The prognostic effect of PTEN expression status in colorectal cancer development and evaluation of factors affecting it: MiR-21 and promoter methylation. J Biomed Sci. 2016. https:\/\/doi.org\/10.1186\/s12929-016-0228-5.","journal-title":"J Biomed Sci"},{"key":"1109_CR37","doi-asserted-by":"publisher","unstructured":"Rezayani S, Farazmandfar T, shahbazi M. Association assessment of platelet derived growth factor B gene polymorphism and its expression status with susceptibility to coronary artery disease. EJMHG. 2017. https:\/\/doi.org\/10.1016\/j.ejmhg.2017.03.004.","DOI":"10.1016\/j.ejmhg.2017.03.004"},{"key":"1109_CR38","doi-asserted-by":"publisher","DOI":"10.2217\/fvl.11.113","author":"J Chung","year":"2011","unstructured":"Chung J, Rossi JJ, Jung U. Current progress and challenges in HIV gene therapy. Future Virol. 2011. https:\/\/doi.org\/10.2217\/fvl.11.113.","journal-title":"Future Virol"},{"key":"1109_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.13731","author":"MA Barry","year":"2020","unstructured":"Barry MA, Rubin JD, Lu S-C. Retargeting adenoviruses for therapeutic applications and vaccines. FEBS Lett. 2020. https:\/\/doi.org\/10.1002\/1873-3468.13731.","journal-title":"FEBS Lett"},{"key":"1109_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(91)90063-g","author":"T Reichert","year":"1991","unstructured":"Reichert T, DeBruy\u00e8re M, Deneys V, T\u00f6tterman T, Lydyard P, Yuksel F, et al. Lymphocyte subset reference ranges in adult Caucasians. Clin Immunol Immunopathol. 1991. https:\/\/doi.org\/10.1016\/0090-1229(91)90063-g.","journal-title":"Clin Immunol Immunopathol"},{"key":"1109_CR41","unstructured":"Murugavel KG, Balakrishnan P, Mohanakrishnan J, Solomon SS, Shankar EM, Muthu Sundaram SP, et al. Establishment of T-lymphocyte subset reference intervals in a healthy adult population in Chennai, India. Indian J Med Res. 2009."},{"key":"1109_CR42","unstructured":"Shete A, Thakar M, Abraham PR, Paranjape R. A review on peripheral blood CD4+ T lymphocyte counts in healthy adult Indians. Indian J Med Res. 2010."},{"key":"1109_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/nrg908","author":"MT McManus","year":"2002","unstructured":"McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet. 2002. https:\/\/doi.org\/10.1038\/nrg908.","journal-title":"Nat Rev Genet"},{"key":"1109_CR44","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.78.5.2601-2605.2004","author":"AT Das","year":"2004","unstructured":"Das AT, Brummelkamp TR, Westerhout EM, Vink M, Madiredjo M, Bernards R, et al. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol. 2004. https:\/\/doi.org\/10.1128\/jvi.78.5.2601-2605.2004.","journal-title":"J Virol"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-021-01109-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-021-01109-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-021-01109-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T10:51:30Z","timestamp":1662634290000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-021-01109-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1109"],"URL":"https:\/\/doi.org\/10.1007\/s13346-021-01109-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-996637\/v1","asserted-by":"object"}]},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,31]]},"assertion":[{"value":"16 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors give consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}